ond-Line Treatment in Patients With Metastatic Colorectal Cancer. J Clin Oncol 28,
(iii) Adverse event rates were comparable across arms with the exception of known toxicities associated with anti-epidermal growth factor receptor (EGFR) therapy such as rash, diarrhea and hypomagnesemia. Vectibix-related grade 3 infusion reactions were reported for two patients (less than 1 percent).
(iv) In general, adverse events rates were comparable across arms with the exception of known toxicities associated with anti-epidermal growth factor receptor (EGFR) therapy such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients.
(v) Malumbres, M. and Barbacid, M. RAS
oncogenes: the first 30 years. Nature Reviews Cancer
. 3:459-65, 2003.
(vi) Karapentis C, S. Snell, L, E. The Laboratory Assessment of KRAS Mutation Status in Colorectal Cancer. Asia, Pacific Journal of Oncology and Hematology
(vii) Friday BB and Adjei AA. K-ras as a target for cancer therapy. Biochim. Biophys. Acta
1756: 127-144, 2005.
(viii) Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10.
Lyon, France: International Agency for Research on Cancer; 2010.
(ix) Ferlay J, Parkin DM, Steliarova-Foucher E Estimates of cancer incidence and mortality in Europe in 2008.
Eur J Cancer. 2010 Mar; 46(4):765-81. Epub 2010 Jan 29.
(x) Vectibix (panitumumab) [prescribing information]. Thousand Oaks, Calif: Amgen; 2011.
(xi) Vectibix (panitumumab) SPC. Thousand Oaks, Calif: Amgen; 2011.
Page: 1 2 3 4 5 6 7 8 9 Related medicine technology :1
. Amgen Donates $1 Million to Help Japanese Disaster Victims2
. Amgen Completes Acquisition of BioVex3
. NBPTS and Amgen Foundation Join to Bolster Science Education4
. Amgen to Present at the Citi 2011 Global Healthcare Conference5
. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing6
. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility7
. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.218
. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive9
. Boehringer Ingelheim to Purchase Amgens Fremont (California) Facility10
. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen11
. Amgen to Present at the 29th Annual JP Morgan Healthcare Conference